This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Inclusion body myositis (IBM) is the most common acquired disease of muscle in adults over the age of 50 years. Although there is compelling evidence for the importance of immunologic abnormalities in its pathogenesis, the cause of the disease is not known, and it is considered to be resistant to treatment with corticosteroids and other conventional immunosuppressive agents. β-Interferon (βIFN), an immunomodulatory cytokine, is a candidate therapeutic agent for IBM.
Method: A 24-week, multicenter, randomized, placebo-controlled, parallel-group clinical trial of 30 μg of β-interferon-1a (βINF1a) administered IM once a week in 30 patients with IBM was conducted. The primary goal was to establish the safety and tolerability of βINF1a in IBM. A secondary goal was to obtain preliminary data on the efficacy of βINF1a by measuring changes from baseline in muscle strength and muscle mass.
Results: Twenty-nine of the 30 subjects enrolled completed the study. Two subjects (one in the placebo group, one in the βINF1a group) experienced severe adverse events. One subject, randomized to receive βINF1a, died from an ischemic bowel after resection of a colonic mass. No subjects required dosage reductions, and the adverse event profile was similar for the placebo and βINF1a groups. There were no significant differences in the changes in muscle strength and muscle mass between the placebo and βINF1a groups at 6 months.
Conclusions: βINF1a at a dose of 30 μg/week IM is well tolerated in IBM. Further studies are needed to establish its therapeutic usefulness in this inflammatory myopathy.
- Received April 10, 2001.
- Accepted July 13, 2001.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
